EA201590325A1 - Улучшенные способы лечения рака с пониженной почечной токсичностью - Google Patents

Улучшенные способы лечения рака с пониженной почечной токсичностью

Info

Publication number
EA201590325A1
EA201590325A1 EA201590325A EA201590325A EA201590325A1 EA 201590325 A1 EA201590325 A1 EA 201590325A1 EA 201590325 A EA201590325 A EA 201590325A EA 201590325 A EA201590325 A EA 201590325A EA 201590325 A1 EA201590325 A1 EA 201590325A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
renal toxicity
reduced renal
improved cancer
cancer patient
Prior art date
Application number
EA201590325A
Other languages
English (en)
Inventor
Тени Боуликас
Джордж Статопоулос
Original Assignee
Тени Боуликас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тени Боуликас filed Critical Тени Боуликас
Publication of EA201590325A1 publication Critical patent/EA201590325A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Предложен способ ингибирования роста опухоли у ракового пациента или лечения ракового пациента, где раковый пациент имеет почечную недостаточность. Данный способ требует введения эффективного количества липоплатина. Пациенту также может вводиться второе химиотерапевтическое лекарственное средство. Вторую химиотерапию можно вводить до или после, или одновременно с терапией липоплатином.
EA201590325A 2012-08-13 2012-08-13 Улучшенные способы лечения рака с пониженной почечной токсичностью EA201590325A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/050630 WO2014027996A1 (en) 2012-08-13 2012-08-13 Improved methods for treating cancer with reduced renal toxicity

Publications (1)

Publication Number Publication Date
EA201590325A1 true EA201590325A1 (ru) 2015-09-30

Family

ID=50101360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590325A EA201590325A1 (ru) 2012-08-13 2012-08-13 Улучшенные способы лечения рака с пониженной почечной токсичностью

Country Status (13)

Country Link
US (1) US20150258140A1 (ru)
EP (1) EP2882420A4 (ru)
JP (1) JP2015528446A (ru)
CN (1) CN104736143A (ru)
AU (1) AU2012387681A1 (ru)
BR (1) BR112015003111A2 (ru)
CA (1) CA2882156A1 (ru)
EA (1) EA201590325A1 (ru)
IN (1) IN2015KN00375A (ru)
MA (1) MA37931A1 (ru)
SG (1) SG11201501146VA (ru)
WO (1) WO2014027996A1 (ru)
ZA (1) ZA201501123B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170186A1 (en) * 2012-05-11 2013-11-14 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169532A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体含有リポソーム製剤
JPH04169531A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体を含有するリポソーム製剤
EP0551169A1 (en) * 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
ES2208946T3 (es) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
DE19954613A1 (de) * 1999-11-12 2001-05-17 Enthone Omi Deutschland Gmbh Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120197060A1 (en) * 2009-06-18 2012-08-02 University Of Utah Research Foundation Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology

Also Published As

Publication number Publication date
BR112015003111A2 (pt) 2017-10-10
CN104736143A (zh) 2015-06-24
AU2012387681A1 (en) 2015-03-05
WO2014027996A1 (en) 2014-02-20
JP2015528446A (ja) 2015-09-28
EP2882420A1 (en) 2015-06-17
IN2015KN00375A (ru) 2015-07-10
SG11201501146VA (en) 2015-05-28
MA37931A1 (fr) 2016-07-29
ZA201501123B (en) 2020-02-26
US20150258140A1 (en) 2015-09-17
EP2882420A4 (en) 2016-06-01
CA2882156A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
PH12016502354A1 (en) Pharmaceutical composition
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MX2020004689A (es) Tratamiento del cancer con inhibidores de tor cinasa.
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MD4643B1 (ru) Новые индолизиновые соединения, способ их получения ифармацевтические композиции их содержащие
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
EA201590325A1 (ru) Улучшенные способы лечения рака с пониженной почечной токсичностью
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
UA88769U (ru) Способ профилактики и лечения доброкачественных дисплазий молочных желез у женщин с ранними потерями беременности
UA101396U (ru) Способ интенсивного лечения злокачественных опухолей